Hanx Biopharmaceuticals (Wuhan) Co Ltd is a China-based company mainly engaged in the research and development of immune-oncology therapies. The Company’s product pipeline comprises clinical stage drug candidates focused on oncology and preclinical stage drug candidates, including Core Product HX009 and Key Products HX301 and HX044, as well as antibody drug conjugate, bispecific antibody and monoclonal antibody for both autoimmune and oncology market. HX009 is a bifunctional anti-programmed cell death protein 1 (PD-1) antibody signal regulatory protein α (SIRPα) fusion protein developed in-house. HX301 is a multi-targeted kinase inhibitor targeting critical pathways such as colony-stimulating factor-1 receptor (CSF1R), AMPK-associated protein kinase 5 (ARK5), FMS-like tyrosine kinase 3 (FLT-3), and cell cycle-independent kinase 4/6 (CDK 4/6). HX044 is a novel bifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody SIRPα fusion protein.

© Copyright 1996-2026 irasia.com Ltd. All rights reserved.

DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website. TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website.